Medicare Coverage Document Compendia View Public Comments

Wolters Kluwer Clinical Drug Information Lexi-Drugs Compendium Revision Request - CAG-00443O

Public Comments

Commenter Comment Information
D’Amato, BSPharm, BCOP, Steven Title: President
Organization: Association of Community Cancer Centers
Date: 05/20/2015
Comment:

May 20, 2015

Cheryl Gilbreath, PharmD, MBA, RPh
Lead Analyst
Centers for Medicare and Medicaid Services
Mail Stop C1-09-06
7500 Security Boulevard
Baltimore, Maryland 21244-1850

BY ELECTRONIC DELIVERY

Re:      Wolters Kluwer Clinical Drug Information Lexi-Drugs Compendium Revision Request - CAG-00443O

Dear Dr. Gilbreath:

The Association of Community Cancer Centers (ACCC) appreciates this

More

Hodorowski RN, Julie Title: Clinical Chemotherapy Coordinator
Date: 04/23/2015
Comment:
This compendium would be a valuable addition.
  • lists combination regimens and expands the acronyms into generic names, includes dosages and frequencies.
  • provides level of evidence for off-label uses
  • includes pediatric indications
  • user friendly, comprehensive and links to many resources
Lee, Judith Title: Senior Compliance Analyst
Organization: Highmark Inc.
Date: 05/12/2015
Comment:
Highmark does not recommend adding the Wolters Kluwer Clinical Drug Information Lexi-Drugs database to the list of compendia for use in the determination of medically-accepted indications of drugs/biologicals used off-label in anti-cancer chemotherapeutic regimens.
Muniz, Omaris Title: VP of Pharmacy Med D
Organization: Triple-S Advantage
Date: 04/21/2015
Comment:
CMS should consider financial impact of requiring additional references to determine medically accepted indications. Lexi-Drugs contains almost the same information as Drug Dex; therefore it would be duplicative to require this reference. Also, when references are incorporated into regulations and guidance as required, the subscription costs for said references increase significantly. As of today, just for drug-dex subscription we pay almost $20,000 per year for a one user access. Then

More

Rice, Michele Title: Pharmacy Director
Organization: Illinois CancerCare, PC
Date: 04/27/2015
Comment:
I am a board-certified oncology pharmacist, practicing in outpatient oncology for fifteen years. The Lexi reference is a reliable reference and one that pharmacists use regularly. I strongly recommend the addition of this reference to the acceptable compendia.
Schlang, Alison Title: Director of Corporate Clinical Pharmacy
Organization: Centura Health
Date: 05/04/2015
Comment:
I agree that Lexi-Drugs should be added as an accepted compendia used by Medicare in this setting.